Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Prognostic and predictive value of an immune infiltration signature in diffuse lower-grade gliomas
Lai-Rong Song, … , Da Li, Jun-Ting Zhang
Lai-Rong Song, … , Da Li, Jun-Ting Zhang
Published March 31, 2020
Citation Information: JCI Insight. 2020;5(8):e133811. https://doi.org/10.1172/jci.insight.133811.
View: Text | PDF
Clinical Research and Public Health Genetics Oncology

Prognostic and predictive value of an immune infiltration signature in diffuse lower-grade gliomas

  • Text
  • PDF
Abstract

BACKGROUND Lower-grade gliomas (LGGs) vary widely in terms of the patient’s overall survival (OS). There is no current, valid method that could exactly predict the survival. The effects of intratumoral immune infiltration on clinical outcome have been widely reported. Thus, we aim to develop an immune infiltration signature to predict the survival of LGG patients.METHODS We analyzed 1216 LGGs from 5 public data sets, including 2 RNA sequencing data sets and 3 microarray data sets. Least absolute shrinkage and selection operator (LASSO) Cox regression was used to select an immune infiltration signature and build a risk score. The performance of the risk score was assessed in the training set (329 patients), internal validation set (140 patients), and 4 external validation sets (405, 118, 88, and 136 patients).RESULTS An immune infiltration signature consisting of 20 immune metagenes was used to generate a risk score. The performance of the risk score was thoroughly verified in the training and validation sets. Additionally, we found that the risk score was positively correlated with the expression levels of TGF-β and PD-L1, which were important targets of combination immunotherapy. Furthermore, a nomogram incorporating the risk score, patient’s age, and tumor grade was developed to predict the OS, and it performed well in all the training and validation sets (C-index: 0.873, 0.881, 0.781, 0.765, 0.721, and 0.753).CONCLUSION The risk score based on the immune infiltration signature has reliable prognostic and predictive value for patients with LGGs and is a potential biomarker for the cotargeting immunotherapy.FUNDING This work was supported by The National Natural Science Foundation of China (grant nos. 81472370 and 81672506), the Natural Science Foundation of Beijing (grant no. J180005), the National High Technology Research and Development Program of China (863 Program, grant no. 2014AA020610), and the National Basic Research Program of China (973 Program, grant no. 2014CB542006).

Authors

Lai-Rong Song, Jian-Cong Weng, Cheng-Bei Li, Xu-Lei Huo, Huan Li, Shu-Yu Hao, Zhen Wu, Liang Wang, Da Li, Jun-Ting Zhang

×

Figure 5

Kaplan-Meier curves based on the IDH and 1p/19q status in the whole data set.

Options: View larger image (or click on image) Download as PowerPoint
Kaplan-Meier curves based on the IDH and 1p/19q status in the whole data...
(A–F) Kaplan-Meier curves of OS of patients with high- and low-risk LGGs based on the IDH and 1p/19q status for 764 patients with IDH mutation (A), 257 patients with WT IDH (B), 349 patients with 1p/19q codeletion (C), 690 patients without 1p/19q codeletion (D), 276 patients with IDH mutation and 1p/19q codeletion (E), and 382 patients with IDH mutation and without 1p/19q codeletion (F). Log-rank test was used for statistical findings.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts